Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis

Jonathan Hogan, Rupali Avasare, Jai Radhakrishnan

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Fingerprint

Dive into the research topics of 'Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis'. Together they form a unique fingerprint.

Medicine & Life Sciences